Alphamab Oncology Dirección

Dirección controles de criterios 2/4

Alphamab Oncology's CEO is Ting Xu, appointed in Nov 2008, has a tenure of 6.67 years. total yearly compensation is CN¥6.88M, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 33.06% of the company’s shares, worth HK$1.23B. The average tenure of the management team and the board of directors is 5.8 years and 5 years respectively.

Información clave

Ting Xu

Chief Executive Officer (CEO)

CN¥6.9m

Compensación total

Porcentaje del salario del CEO	95.2%
Permanencia del CEO	16yrs
Participación del CEO	33.1%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ting Xu en comparación con los beneficios de Alphamab Oncology?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥216m
Mar 31 2024	n/a	n/a	-CN¥213m
Dec 31 2023	CN¥7m	CN¥7m	-CN¥211m
Sep 30 2023	n/a	n/a	-CN¥214m
Jun 30 2023	n/a	n/a	-CN¥218m
Mar 31 2023	n/a	n/a	-CN¥272m
Dec 31 2022	CN¥7m	CN¥6m	-CN¥326m
Sep 30 2022	n/a	n/a	-CN¥309m
Jun 30 2022	n/a	n/a	-CN¥292m
Mar 31 2022	n/a	n/a	-CN¥352m
Dec 31 2021	CN¥7m	CN¥5m	-CN¥412m
Sep 30 2021	n/a	n/a	-CN¥502m
Jun 30 2021	n/a	n/a	-CN¥592m
Mar 31 2021	n/a	n/a	-CN¥510m
Dec 31 2020	CN¥5m	CN¥4m	-CN¥428m
Sep 30 2020	n/a	n/a	-CN¥652m
Jun 30 2020	n/a	n/a	-CN¥877m
Mar 31 2020	n/a	n/a	-CN¥851m
Dec 31 2019	CN¥5m	CN¥3m	-CN¥833m

Compensación vs. Mercado: Ting's total compensation ($USD969.67K) is above average for companies of similar size in the Hong Kong market ($USD399.57K).

Compensación vs. Ingresos: Ting's compensation has increased whilst the company is unprofitable.

CEO

Ting Xu (51 yo)

16yrs

Permanencia

CN¥6,877,000

Compensación

Dr. Ting Xu, Ph D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008.Dr. Xu serves as Executive Director at Alphamab Oncology since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ting Xu	Founder	16yrs	CN¥6.88m	33.06% HK$ 1.2b
Yang Liu	VP of Corporate Operations & Executive Director	6.1yrs	CN¥2.97m	sin datos
Yumin Wan	Vice President of Government Affairs & Public Relations	5.8yrs	sin datos	sin datos
Mike Liu	Senior Vice President of Business Development	6.5yrs	sin datos	sin datos
Jing Han	Chief Commercial Officer	3yrs	sin datos	sin datos
Lok Yee Chan	Joint Company Secretary	4.3yrs	sin datos	sin datos
Qiulan Cheng	Joint Company Secretary	less than a year	sin datos	sin datos

5.8yrs

Permanencia media

51.5yo

Promedio de edad

Equipo directivo experimentado: 9966's management team is seasoned and experienced (5.8 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ting Xu	Founder	6.7yrs	CN¥6.88m	33.06% HK$ 1.2b
Yang Liu	VP of Corporate Operations & Executive Director	6.1yrs	CN¥2.97m	sin datos
Cheng Wei	Independent Non-Executive Director	5yrs	CN¥396.00k	sin datos
Man Cho	Non-Executive Director	less than a year	sin datos	0.11% HK$ 4.0m
Jason J. Luke	Member of Scientific Advisory Board	no data	sin datos	sin datos
Yiping Yang	Member of Scientific Advisory Board	no data	sin datos	sin datos
Dong Wu	Independent Non-Executive Director	5yrs	CN¥396.00k	sin datos
Lei Zheng	Member of Scientific Advisory Board	no data	sin datos	sin datos
Zihai Li	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Zijian Guo	Independent Non-Executive Director	3.3yrs	CN¥378.00k	sin datos

5.0yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: 9966's board of directors are considered experienced (5 years average tenure).

Alphamab Oncology Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Alphamab Oncology Announces Board and Board Committee Changes

Insufficient new directors

Alphamab Oncology, Annual General Meeting, Jun 12, 2024

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee

Alphamab Oncology Announces Board and Committee Changes

Alphamab Oncology, Annual General Meeting, Jun 10, 2022

Recent updates

Alphamab Oncology Announces Board and Board Committee Changes

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

New major risk - Share price stability

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-Her2 Bispecific Adc Jskn003 At the Esmo Congress 2024

Alphamab Oncology Announces Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced SQ NSCLC

Insufficient new directors

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

Alphamab Oncology (SEHK:9966) commences an Equity Buyback Plan for 96,492,380 shares, representing 10% of its issued share capital, under the authorization approved on June 12, 2024.

First half 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.042 loss in 1H 2023)

Alphamab Oncology to Report First Half, 2024 Results on Aug 15, 2024

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology Presents Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

Alphamab Oncology Provides Updates in Relation to A Phase III Clinical Trial of KN046 for the Treatment of Advanced PDAC

New major risk - Share price stability

Alphamab Oncology Announces First Patient Has Been Successfully Dosed in A Phase I Clinical Trial of JSKN016

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Alphamab Oncology Announces Updates on Results of a Phase I Clinical Trial of JSKN003 for the Treatment of HER2-Expressing Advanced Solid Tumors for Presentation at 2024 AACR Annual Meeting

Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Alphamab Oncology, Annual General Meeting, Jun 12, 2024

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

Alphamab Oncology Announces Results of Phase II Clinical Study of Kn046 Plus Chemotherapy as First-Line Treatment for Metastatic Nsclc Were Published in Cell Reports Medicine

Alphamab Oncology to Report Fiscal Year 2023 Results on Mar 28, 2024

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Alphamab Oncology Announces Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Alphamab Oncology Announces Phase I/II Clinical Trial of Jskn033 Independently Developed by Group for the Treatment of Human Epidermal Growth Factor Receptor

Alphamab Oncology Announces First Patient Dosed in Phase Iii Study of Jskn003 for the Treatment of Advanced Her2-Low Breast Cancer

Alphamab Oncology Announces Preliminary Results of a Phase I Clinical Trial of JSKN003 in Australia for the Treatment of Her2-Expressing Advanced Solid Tumors

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

Alphamab Oncology Announces Results of Two Studies of HER2 Bispecific Antibody KN026 At the European Society of Medical Oncology

New minor risk - Profitability

First half 2023 earnings released: CN¥0.042 loss per share (vs CN¥0.16 loss in 1H 2022)

Alphamab Oncology Announces Research Updates on KN046 and KN026 for Presentation At ESMO Congress 2023

Alphamab Oncology to Report First Half, 2023 Results on Aug 23, 2023

Alphamab Oncology Announces First Patient Successfully Dosed in Randomized, Controlled, Open-Label, Multi-Center, Phase III Clinical Trial of Kn026 in China

Alphamab Oncology Resignation of Xu Zhan Kevin as Non-Executive Director and Member of the Strategy Committee

Alphamab Oncology Updates Clinical Research Data for Kn026 in Combination with Kn046 in Her2-Positive Solid Tumors At the Asco 2023 Annual Meeting

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Alphamab Oncology Updates in Relation to A Phase Iii Clinical Trial of Kn046 for the Treatment of Advanced SQ NSCLC

Consensus revenue estimates decrease by 13%, EPS upgraded

No longer forecast to breakeven

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Consensus revenue estimates decrease by 15%

Alphamab Oncology has completed a Follow-on Equity Offering in the amount of HKD 380.5 million.

Forecast to breakeven in 2025

Alphamab Oncology Presents Clinical Data of Kn026 Combined with Docetaxel as Neoadjuvant Treatment for Her2-Positive Early or Locally Advanced Breast Cancer At Sabcs 2022

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022

Alphamab Oncology Announces Results from Three Clinical Studies of KN026 and KN046

Alphamab Oncology Receives IND Approval by NMPA for A Phase Ia/Ib Clinical Trial of JSKN003 for the Treatment of Advanced Solid Tumors

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Alphamab Oncology Announces First Patient Dosed in A Phase I Clinical Trial of JSKN003 (KN026-ADC) in Australia for the Treatment of Advanced Solid Tumors

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology Announces Updates on Clinical Data of KN046 and KN026

Alphamab Oncology to Report First Half, 2022 Results on Aug 31, 2022

Alphamab Oncology Announces First Patient Dosed in Phase II Clinical Trial of KN046 Combined with Axitinib for the First-Line Treatment of Advanced NSCLC

Alphamab Oncology Announces Board and Committee Changes

Alphamab Oncology Announces First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052

Alphamab Oncology Announces First Patient Dosed in A Phase Ii Clinical Trial of Kn026 Combined with Palbociclib and Fulvestrant for the Treatment of Locally Advanced Unresectable or Metastatic Her2-Positive Breast Cancer

Is Alphamab Oncology (HKG:9966) A Risky Investment?

No longer forecast to breakeven

Alphamab Oncology Updates on Clinical Data of Kn046 in Combination with Kn026 for the Treatment of Her2-Positive Solid Cancer for Presentation at 2022 AACR Annual Meeting